In the latest trading session,, 31.64 million Kazia Therapeutics Limited ADR (NASDAQ:KZIA) shares changed hands as the company’s beta touched 2.51. With the company’s most recent per share price at $9.16 changing hands around $3.9 or 74.30% at last look, the market valuation stands at $6.14M. KZIA’s current price is a discount, trading about -762.45% off its 52-week high of $79.00. The share price had its 52-week low at $2.86, which suggests the last value was 68.78% up since then.

Analysts gave the Kazia Therapeutics Limited ADR (KZIA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended KZIA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.

Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information

Instantly KZIA is in green as seen in intraday trades today. With action 71.06%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.50%, with the 5-day performance at 71.06% in the green. However, in the 30-day time frame, Kazia Therapeutics Limited ADR (NASDAQ:KZIA) is 157.23% up.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.47%.

KZIA Dividends

Kazia Therapeutics Limited ADR is expected to release its next quarterly earnings report in July.

SUSQUEHANNA INTERNATIONAL GROUP, LLP holds the second largest percentage of outstanding shares, with 0.173% or 41478.0 shares worth $9457.0 as of 2024-06-30.

With 296.0 shares estimated at $3081.0 under it, the former controlled 0.03% of total outstanding shares.